Meeting
2014 Genitourinary Cancers Symposium
Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC): What is effective? Data from the German RCC registry.
Authors
Lothar Mueller
Oncologie Leer - Emden, Leer, Germany
Lothar Mueller , Peter J. Goebell , A. Lueck , Friedrich Overkamp , Michele Vogt , Norbert Marschner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 499)
DOI
10.1200/jco.2014.32.4_suppl.499
Abstract #
499
Poster Bd #
G14
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan
Poster
2022 ASCO Genitourinary Cancers Symposium
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
First Author: Sophie Laramee
Poster
2018 Genitourinary Cancers Symposium
Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).
First Author: Paul L. de Souza